Ignite Creation Date:
2024-05-06 @ 8:23 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06364501
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-17
First Post:
2024-04-02
Brief Title:
Phase 1 Trial of KH801
Sponsor:
Beijing Kanghong Biopharmaceutical Co Ltd
Organization:
Chengdu Kanghong Pharmaceutical Group Co Ltd
Study Overview
Official Title:
A Phase I Clinical Study Evaluating the Safety Tolerability Pharmacokinetic Characteristics and Preliminary Anti-tumor Activity of KH801 Injection in Patients With Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
KH801 is a injection used for advanced solid tumors which must be diluted with 5 Dextrose Or 09 sodium chloride Injection
This study is expected to include a total of approximately 17-42 participants
This study is expected to include a total of approximately 17-42 participants
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None